169 related articles for article (PubMed ID: 23960792)
1. The use of pharmacoeconomic evidence to support formulary decision making in Saudi Arabia: Methodological recommendations.
Al Aqeel SA; Al-Sultan M
Saudi Pharm J; 2012 Jul; 20(3):187-94. PubMed ID: 23960792
[TBL] [Abstract][Full Text] [Related]
2. The role of pharmacoeconomics in formulary decision making in different hospitals in Riyadh, Saudi Arabia.
Alsultan MS
Saudi Pharm J; 2011 Jan; 19(1):51-6. PubMed ID: 23960742
[TBL] [Abstract][Full Text] [Related]
3. Pharmacoeconomics and formulary decision making.
Sanchez LA
Pharmacoeconomics; 1996; 9 Suppl 1():16-25. PubMed ID: 10160112
[TBL] [Abstract][Full Text] [Related]
4. Use of pharmacoeconomic data in making hospital formulary decisions.
Odedina FT; Sullivan J; Nash R; Clemmons CD
Am J Health Syst Pharm; 2002 Aug; 59(15):1441-4. PubMed ID: 12166044
[TBL] [Abstract][Full Text] [Related]
5. Institutional formularies: the relevance of pharmacoeconomic analysis to formulary decisions.
Lipsy RJ
Pharmacoeconomics; 1992 Apr; 1(4):265-81. PubMed ID: 10147017
[TBL] [Abstract][Full Text] [Related]
6. [Cost-effectiveness of new drugs impacts reimbursement decision making but room for improvement].
Hoomans T; van der Roer N; Severens JL; Delwel GO
Ned Tijdschr Geneeskd; 2010; 154():A958. PubMed ID: 20699045
[TBL] [Abstract][Full Text] [Related]
7. The role of pharmacoeconomics in current Indian healthcare system.
Ahmad A; Patel I; Parimilakrishnan S; Mohanta GP; Chung H; Chang J
J Res Pharm Pract; 2013 Jan; 2(1):3-9. PubMed ID: 24991597
[TBL] [Abstract][Full Text] [Related]
8. Attitude and perception of pharmacists and healthcare professionals about the criteria used in drug formulary selection in the United Arab Emirates.
Al-Hemyari SS; Mohamed Noor DA; El-Dahiyat F
J Pharm Policy Pract; 2022 Oct; 15(1):67. PubMed ID: 36258258
[TBL] [Abstract][Full Text] [Related]
9. Pharmacoeconomic analysis in formulary decisions: an international perspective.
Johnson JA; Bootman JL
Am J Hosp Pharm; 1994 Oct; 51(20):2593-8. PubMed ID: 7847423
[TBL] [Abstract][Full Text] [Related]
10. Application of pharmacoeconomics to formulary decision making in managed care organizations.
Suh DC; Okpara IR; Agnese WB; Toscani M
Am J Manag Care; 2002 Feb; 8(2):161-9. PubMed ID: 11858228
[TBL] [Abstract][Full Text] [Related]
11. Methods for the comparative evaluation of pharmaceuticals.
Zentner A; Velasco-Garrido M; Busse R
GMS Health Technol Assess; 2005 Nov; 1():Doc09. PubMed ID: 21289930
[TBL] [Abstract][Full Text] [Related]
12. Formulary management in the Department of Defense.
Trice S; Devine J; Mistry H; Moore E; Linton A
J Manag Care Pharm; 2009 Mar; 15(2):133-46. PubMed ID: 19236127
[TBL] [Abstract][Full Text] [Related]
13. The Use of Economic Evidence to Inform Drug Pricing Decisions in Jordan.
Hammad EA
Value Health; 2016; 19(2):233-8. PubMed ID: 27021758
[TBL] [Abstract][Full Text] [Related]
14. The pharmacoeconomic picture in Saudi Arabia.
Alkhenizan A
Expert Rev Pharmacoecon Outcomes Res; 2014 Aug; 14(4):483-90. PubMed ID: 24953076
[TBL] [Abstract][Full Text] [Related]
15. Barriers and Facilitators of Pharmacoeconomic Studies: A Review of Evidence from the Middle Eastern Countries.
Alzarea AI; Khan YH; Alanazi AS; Butt MH; Almalki ZS; AlAhmari AK; Alsahali S; Mallhi TH
Int J Environ Res Public Health; 2022 Jun; 19(13):. PubMed ID: 35805521
[TBL] [Abstract][Full Text] [Related]
16. Recommendations for Reporting Pharmacoeconomic Evaluations in Egypt.
Elsisi GH; Kaló Z; Eldessouki R; Elmahdawy MD; Saad A; Ragab S; Elshalakani AM; Abaza S
Value Health Reg Issues; 2013; 2(2):319-327. PubMed ID: 29702884
[TBL] [Abstract][Full Text] [Related]
17. Unravelling drug reimbursement outcomes: a comparative study of the role of pharmacoeconomic evidence in Dutch and Swedish reimbursement decision making.
Franken M; Nilsson F; Sandmann F; de Boer A; Koopmanschap M
Pharmacoeconomics; 2013 Sep; 31(9):781-97. PubMed ID: 23839699
[TBL] [Abstract][Full Text] [Related]
18. Using economic evaluations to make formulary coverage decisions. So much for guidelines.
Anis AH; Gagnon Y
Pharmacoeconomics; 2000 Jul; 18(1):55-62. PubMed ID: 11010604
[TBL] [Abstract][Full Text] [Related]
19. A guideline for the use of pharmacoeconomic models of diabetes treatment in the US managed-care environment.
Veenstra DL; Ramsey SD; Sullivan SD
Pharmacoeconomics; 2002; 20 Suppl 1():21-30. PubMed ID: 12036381
[TBL] [Abstract][Full Text] [Related]
20. Revitalizing oncology medications access in Saudi Arabia: Current challenges and recommendations by the Saudi Oncology Pharmacy Assembly.
Alkhudair N; Howaidi J; Alnuhait M; Alshamrani M; Khan M; Alharbi A; Alnajjar F; Bajnaid E; Almodaheem H; Alhowimel M; Alzahrani A; Khardaly A; Alnahedh M; Elsoudi H; Alabdulkareem H; Alrashidan A; Alzahrani M; Alrajhi A
J Oncol Pharm Pract; 2024 Feb; ():10781552241232697. PubMed ID: 38377985
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
